Home

Insights

Glaxosmithkline Pharmaceuticals Ltd P/E Ratio

Glaxosmithkline Pharmaceuticals Ltd P/E Ratio

download
stocks purchased

₹ 2.0 Cr

Volume transacted

stocks purchased

8.6 K

stocks traded

Image

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO

PE

53.5

Last updated : 19 May 01:55 AM

Key Highlights

    The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd is 53.5 as of 19 May 01:55 AM .a1#The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 49.4 on March 2019 to 36.7 on March 2023 . This represents a CAGR of -5.77% over 5 years. a1#The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2355 as of 18 May 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 27.2. The PE Ratio of Finance industry is 13.6. The PE Ratio of IT - Software industry is 27.9. The PE Ratio of Pharmaceuticals industry is 27.7. The PE Ratio of Retail industry is 94.8. The PE Ratio of Textiles industry is 21.1. In 2023a1#The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 22020 crore on March 2019 to ₹ 22431 crore on March 2023 . This represents a CAGR of 0.37% over 5 years. a1#The Revenue of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 775.76 crore to ₹ 962.03 crore over 8 quarters. This represents a CAGR of 11.36% a1#The EBITDA of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 179.58 crore to ₹ 289.49 crore over 8 quarters. This represents a CAGR of 26.97% a1#The Net Profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 119.28 crore to ₹ 194.48 crore over 8 quarters. This represents a CAGR of 27.69% a1#The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 79.65 % on March 2019 to 89.2 % on March 2023 . This represents a CAGR of 2.29% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1949.4
Mar '20226.4
Mar '2168.1
Mar '2216.6
Mar '2336.7

Fundamental Metrics

Market Cap

38,820 Cr

EPS

37.9

P/E Ratio (TTM) *

53.5

P/B Ratio (TTM) *

22.3

Day’s High

2405.0

Day’s Low

2340.0

DTE *

0.0

ROE *

42.1

52 Week High

2649.95

52 Week Low

1265.0

ROCE *

57.4

* All values are consolidated

* All values are consolidated

Image

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO

PRICE

2355.75

64.20(2.80%)

stock direction

Last updated : 18 May 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

0

S

Weakness

4

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value

Market Value

34,285

Asset Value

2,128

15.1 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

528 Cr

53.5 X

PE Ratio

Market Cap

₹34285Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

528 Cr

53.5 X

PE Ratio

Market Cap

₹34285Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Glaxosmithkline Pharmaceuticals Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Glaxosmithkline Pharmaceuticals Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Glaxosmithkline Pharmaceuticals Ltd's Share Price stands at 2355.75. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-05-18T00:00:00 is 37.86. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 2355.75/ 37.86= 53.46.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Glaxosmithkline Pharmaceuticals Ltd's stock is trading at approximately 53.46 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Glaxosmithkline Pharmaceuticals Ltd’s PE Ratio (BSE: GLAXO)

    The Price-to-Earnings (PE) ratio, used to assess Glaxosmithkline Pharmaceuticals Ltd's stock (BSE: GLAXO), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '1922020
Mar '2021095
Mar '2124401
Mar '2228171
Mar '2322432

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22776
Sep '22939
Dec '22826
Mar '22826
Jun '23815
Sep '23985
Dec '23833
Mar '23962

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '22180
Sep '22279
Dec '22241
Mar '22208
Jun '23198
Sep '23318
Dec '2383
Mar '23289

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '22119
Sep '22193
Dec '22165
Mar '22133
Jun '23132
Sep '23218
Dec '2346
Mar '23194

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1980
Mar '20616
Mar '21142
Mar '2290
Mar '2389

* All values are a in %

About Glaxosmithkline Pharmaceuticals Ltd

About Glaxosmithkline Pharmaceuticals Ltd

    It is a subsidiary of GlaxoSmithKline plc, UK, one of the world's leading research-based pharmaceutical and healthcare companies. In 1961, the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The company's name was changed from Glindia Ltd to Glaxo India Ltd. In the year 1990, the production of the bulk drug, cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. They increased the production capacity of Solids including Powders and Ointments from 1550 tonnes to 2225 tonnes. Formulations of Atorvastatin and Rosuvastatin tablets were launchec in Cardiology under the brand names 'Lilo' and 'Rosutec' respectively. This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis. During the quarter ended 30 September 2016, the company successfully launched Priorix-Tetra, a combined measles, mumps, rubella and varicella vaccine. During the quarter ended 31 December 2017, the company received the money in advance towards disposal of Thane land. During the quarter ended 31 March 2018, the company successfully launched Biopatch, a hydrophilic wound dressing that is used to cover a wound caused by the use of percutaneous medical devices.

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GlaxoSmithKline Pharmaceuticals to conduct AGM

GlaxoSmithKline Pharmaceuticals announced that the 99th Annual General Meeting(AGM) of the...

Read more

17 May 2024 16:48

News

Board of GlaxoSmithKline Pharmaceuticals recommends Final Dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

17 May 2024 14:03

News

GlaxoSmithKline Pharmaceuticals to declare Quarterly Result

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

20 Apr 2024 18:27

News

Glaxosmithkline Pharmaceuticals Ltd slips for fifth straight session

Glaxosmithkline Pharmaceuticals Ltd is down for a fifth straight session today. The stock ...

Read more

11 Mar 2024 13:35

News

GSK Pharma slumps as PAT drops 72% YoY in Q3 FY24

Revenue from operations rose marginally to Rs 805.26 crore in the quarter ended 31 Decembe...

Read more

13 Feb 2024 10:41

News

Glaxosmithkline Pharmaceuticals Ltd slips for fifth straight session

Glaxosmithkline Pharmaceuticals Ltd is down for a fifth straight session today. The stock ...

Read more

13 Feb 2024 13:35

Product Composition by Percentage (Revenue)

FAQs for PE of Glaxosmithkline Pharmaceuticals Ltd

What is Glaxosmithkline Pharmaceuticals Ltd current share price?

The current market price of Glaxosmithkline Pharmaceuticals Ltd as of May 19, 2024 is ₹2355.75.

Is Glaxosmithkline Pharmaceuticals Ltd a good investment?

As per BlinkX Score Glaxosmithkline Pharmaceuticals Ltd scores 19 in Revenue, 97 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Glaxosmithkline Pharmaceuticals Ltd's total net assets?

According to Glaxosmithkline Pharmaceuticals Ltd's most recent financial filings, the company's net assets total ₹2127.7 Cr.

Is Glaxosmithkline Pharmaceuticals Ltd making a profit or loss?

Glaxosmithkline Pharmaceuticals Ltd's net Profit as of May 19, 2024 is close to ₹528 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199